TTK-IN-5

TTK-IN-5 is an orally active covalent threonine tyrosine kinase (TTK) inhibitor with selectivity (IC50 = 8.918 nM) . TTK-IN-5 exhibits anti-proliferative potencies against MDA-MB-231, A2780, HCT116, HCC1569 and MKN1 cell lines (IC50 values of 0.113 μM, 0.476 μM, 3.136 μM, 3.649 μM, and 1.856 μM, respectively) . TTK-IN-5 potently suppresses tumor growth without notable toxicity in A2780 and MDA-MB-231 xenograft mouse models. TTK-IN-5 can be used for the research of cancer such as breast cancer and ovarian cancer[1].

Product Specifications

UNSPSC

12352005

Target

Mps1

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Field of Research

Cancer

Smiles

COC1=CC=C(OC2=NC3=C(C4=CC(C)=C(C(NC5CC5)=O)C=C4)C=NN3C(N(C(C=C)=O)C)=C2)C(F)=C1F

Molecular Formula

C28H25F2N5O4

Molecular Weight

533.53

References & Citations

[1]JIANG C H, et al. Discovery and optimization of potent covalent threonine tyrosine kinase (TTK) inhibitors for the treatment of triple-negative breast cancer[J]. European Journal of Medicinal Chemistry, 2026, 302 (Part 1) :118271.